Company profile

 
AiCuris was created in 2006 as a spin-out of Bayer’s anti-infective division and is backed by the Strüngmann family office as lead investor and other private investors well known in Germany ). We develop innovative drugs against severe and life-threatening infectious diseases. By targeting indications with high medical need, as well as preparing for pandemic and resistance emergencies, we focus on markets where no efficient solution is available and bring novel approaches into a long-underserved sector.

 

 

 


Our Mission

Fighting infectious diseases of the 21st century

 
With a staff of ~70 employees, AiCuris’ head office and research laboratories are located at the Pharma- and Chemistry Park in Wuppertal, Germany, where the company occupies 5.500 square meters, including 3.500 square meters of purpose-built biology and pharmacokinetics facilities. Committed to making the difference, we have more than 15 years of experience in advancing novel approaches. The Company’s first product, Letermovir (Prevymis®), a first-in-class therapy for human cytomegalovirus (HCMV) infections, was successfully out-licensed to Merck & Co., is marketed since 2017 with growing revenues, and has won several prizes for providing a paradigm shift in transplant medicine.

 


Our path to success

 

 

 


 

Related:

 


Link to Corporate Video
Link zum Unternehmens-Video